Case report of pulmonary mucormycosis in children with diabetes mellitus type 1
https://doi.org/10.21508/1027-4065-2025-70-4-78-83
Abstract
Mucormycosis is a life-threatening, rare disease caused by the fibrous saprophytic fungus Mucorales of the zygomycetes group, which is more often pathogenic in immunocompromised individuals. The disease has a high mortality rate, but aggressive medical and surgical treatment can result in survival rates exceeding 80%. Depending on the organ affected, there are several main forms: rhino-cerebral, pulmonary, cutaneous, gastrointestinal and disseminated forms. The article is devoted to the analysis of a clinical case of a 15–year-old patient with type 1 diabetes mellitus with pulmonary form of mucormycosis. Emphasis is made on the most effective combination of therapy of mucormycosis with Amphoterecin B and Izavuconazole, nevertheless difficulties in diagnosis led to pneumonectomy. Due to the high mortality rate, physicians need to make correct and timely decisions regarding suspected cases to avoid misdiagnosis and untimely treatment.
About the Authors
A. V. LipunovRussian Federation
117997 Moscow
O. G. Kositskaya
Russian Federation
117997 Moscow
S. Y. Semykin
Russian Federation
119571 Moscow
A. M. Michopulos
Russian Federation
119571 Moscow
P. V. Shumilov
Russian Federation
117997 Moscow
References
1. Popova M.O., Rogacheva Yu. A. Mucormycosis: Current diagnostic and treatment options, current problems and new trends in therapy. СMAХ. 2021; 3: 226–238 (in Russ.)] DOI: 10.36488/cmac.2021.3.226–238
2. Samsonova M.V., Chernyaev A.L., Lebedin Yu.S, Mihajlichenko K.Yu., Polivanova A.E. Mucormycosis of the lung. Pul’monologiya 2018; 28 (2): 243–247. (in Russ.) DOI: 10.18093/0869–0189–2018–28–2–243–247]
3. Taraskina A.E., Pchelin I.M., Ignat’eva S.M., Spiridonova V.A., Uchevatkina A.E., Filippova L.V., et al Molecular genetic methods for the detection and species identification of fungi of the order Mucorales according to global guidelines for the diagnosis and therapy of mucormycosis (literature review). Problemy medicinskoj mikologii 2020; 22(1): 3–14 (in Russ.)] DOI: 10.24412/1999–6780–2020–1–3–14
4. Makarov AA, Orazvaliev AI, Ushakov RV, Zhabko EV. Clinical case of rhino-orbital-cerebral mucormycosis associated with COVID-19 and diabetes. Rossijskaya rinologiya 2022; 30(3): 210-216. (in Russ.)] DOI: 10.17116/rosrino202230031210
5. E.V., Gurov A.V., Yushkina M.A. Diabetes mellitus and pyoinflammatory diseases of ENT organs. Saharnyj diabet 2012; 15(2): 54–59. (in Russ.)] DOI: 10.14341/2072–0351–5519
6. MSD manuals, mucormicosis.Paschalis Vergidis, MD, MSc, Mayo Clinic College of Medicine & Science. November, 2023 https://www.msdmanuals.com/ru/home/инфекции/грибковые-инфекции/мукормикоз / Ссылка активна на 28.06.2025
7. Dreval’ A.V., Gubkina V.A., Kamynina T.S., Loseva V.A., Mel’nikova E.V., Zenger V.G., et al. Three cases of mucoromycosis in patients with diabetes mellitus (Moscow region). Problemy Endokrinologii 2004; 50(5): 39–44. (in Russ.)] DOI: 10.14341/probl11524
8. Kukushkin G.V., Starostina E.G. Infections in diabetics (lecture). RMJ. 2016; 20: 1327–1333. (in Russ.)]
9. Rammaert B., Lanternier F., Poirée S., Kania R., Lortholary O. Diabetes and mucormycosis: a complex interplay. Diabetes Metab. 2012; 38(3): 193–204. DOI: 10.1016/j.diabet.2012.01.002
10. Khostelidi S.N., Zaytsev V.A., Pelikh E.V., Yashina E.V., Rodionova O.N., Bogomolova T.S., et al. Mucormycosis following COVID-19: clinical case and literature review СMAХ 2021; 23(3): 255–262 (in Russ.)] DOI: 10.36488/cmac.2021.3.255–262
11. Balushi A.A., Ajmi A.A., Sinani Q.A., Menon V., Berieki Z.A., Shezawi A.A., et al. COVID-19–Associated Mucormycosis: An Opportunistic Fungal Infection. A Case Series and Review. Int J Infect Dis. 2022; 121: 203– 210. DOI: 10.1016/j.ijid.2022.05.005
12. Chamilos G., Lewis R.E., Kontoyiannis D.P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008; 47(4): 503–509. DOI: 10.1086/590004
13. Maertens J.A., Raad I.I., Marr K.A., Patterson T.F., Kontoyiannis D.P., Cornely O.A., et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet.2016; 387(10020): 760–769. DOI: 10.1016/S0140–6736(15)01159–9
14. Abdulkader R.S., Mohan M., Saravanakumar D., Ponnaiah M., Bhatnagar T., Devika S., et al. All-India Mucormycosis Consortium. Survival and quality-of-life in mucormycosis: a multicentric ambispective cohort study. Clin Microbiol Infect. 2025; 12:S1198–743X(25)00286–1. DOI: 10.1016/j.cmi.2025.06.001
15. Damaraju V., Agarwal R., Dhooria S., Sehgal I.S., Prasad K.T., Gupta K., et al. Isolated tracheobronchial mucormycosis: Report of a case and systematic review of literature. Mycoses. 2023; 66(1): 5–12. DOI: 10.1111/myc.13519
Review
For citations:
Lipunov A.V., Kositskaya O.G., Semykin S.Y., Michopulos A.M., Shumilov P.V. Case report of pulmonary mucormycosis in children with diabetes mellitus type 1. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2025;70(4):78–83. https://doi.org/10.21508/1027-4065-2025-70-4-78-83
Email this article 